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ABSTRACT

Ammar, Hala Mustafa. M.S., Department of Pharmacology and Toxicology, Wright
State University, 2014. The Modulatory Role of Circulating Microvesicles in
Endothelial Progenitor Cell Function Is Altered in T2DM.

Circulating microvesicles (cMVs) are the extracellular MVs released from
the cells in the blood and on the vascular wall. Our previous study demonstrates
that cMVs of diabetic mouse are detrimental to endothelial progenitor cells
(EPCs), which are known to be very important for maintaining normal endothelial
function and structure. In this study, we compared the levels of circulating EPCs
and EPC-derived MVs (EPC-MVs) in diabetic and healthy subjects. Also, the
migration ability, apoptosis rate and reactive oxygen species (ROS) production of
EPCs cultured from diabetic and healthy subjects were determined. More
importantly, we evaluated whether cMVs from healthy subjects (ch-MVs)
improves the function of EPCs from diabetic patients (d-EPCs), and whether
cMVs from diabetic patients (cd-MVs) impairs the function of EPCs from healthy
subjects (h-EPCs). The d-EPCs or h-EPCs were incubated with ch-MVs or cdMVs for 24 hours. The migration ability of EPCs was analyzed by an assay kit.
The apoptotic rate and ROS production were analyzed by labeling with propidium
iodide (PI) and dihydroethidium (DHE) respectively, followed with flow
cytometeric analysis. Our data showed that (1) there was a decrease in EPCs
iii

and an elevation in EPC-MVs in diabetic patients when compared to healthy
subjects; (2) The migration ability of d-EPCs were decreased, and the apoptosis
rate and ROS production were increased in d-EPCs; (3) ch-MVs improve the
function of d-EPC through improving its migration ability and decreasing the
apoptosis and ROS production; (4) cd-MVs increase h-EPC apoptosis, and
increase ROS production. We conclude that cMVs modulate EPC function and
this role of cMVs is reversed in diabetes with the mechanism linked to ROS
production.
Abbreviations
cMVs

Circulating Microvesicles.

ch-MVs

Circulating Microvesicles from Healthy Subjects.

cd-MVs

Circulating Microvesicles from Diabetic Patients .

EPCs

Endothelial Progenitor Cells.

h-EPCs

Endothelial Progenitor cells from Healthy Subject.

d-EPCs

Endothelial Progenitor cells from Diabetic Patients.

ROS

Reactive Oxygen Species.
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1. Introduction.
Diabetes mellitus (DM) is one of the major risk factors for vascular disease that is
considered the leading cause of death in the United States. The incidence and
mortality of cardiovascular disease are two- to eight fold higher in persons with
diabetes than in those without diabetes (Howard et al., 2002). DM, is a chronic
metabolic disease characterized by a glucotoxicity and lipotoxicity, considered as
a principle cause of vascular endothelial damage, which ultimately leads to
various cardiovascular complications. Endothelium dysfunction is a key initiator
for vascular injury, and is characterized by a pro-inflammatory, pro-coagulative,
and pro-vasoconstrictive endothelial constitution. (Burger et al., 2012). It results
from increased oxidative stress in the vascular cells that is mostly attributable to
NADPH oxidase (Nox) activation, and endothelial nitric oxide synthase (eNOS)
uncoupling (Zhang et al., 2008). DM is associated with endothelial dysfunction
which could be linked with functional impairment of endothelial progenitor cells
(EPCs) (Thum et al., 2007).
EPCs are defined as bone marrow (BM)-derived circulating immature cells with
the ability to differentiate into mature endothelial cells (ECs). EPCs are known to
play important roles in maintaining normal endothelial function and structure by
repairing or replacing dysfunctional or injured ECs. EPCs have been established
to have therapeutic effects on cardiovascular disease through promoting
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angiogenesis (De Biase et al., 2013). Our laboratory has demonstrated that
EPCs also linked to ischemic stroke outcome (Chen et al, 2011). So the
reduction in the number of EPCs or impairment in their functions may directly
affect the endothelium balance and lead to endothelial dysfunction. DM has been
reported to impair EPC proliferation, differentiation, adhesion, mobilization, and
survival. (Avogaro et al., 2011; Petrelli et al., 2010 & Chen et al., 2011). As
reported by Oikaw and Busik (Oikaw et al., 2010& Busik et al., 2009), one of the
leading mechanisms, which impair EPC functions in DM, is BM alteration through
oxidative stress; including BM neuropathy and microangiopathy. Likewise,
studies also showed a negative association for EPC dysfunction with insulin, as
well as with glucose level. Insulin has been demonstrated to have a detrimental
effects to EPC in vitro and in vivo (Humper et al., 2005; 2008). On the other
hand, Lev et al have explored that EPCs number is increase and its function is
improved after intensive glycemic control program (Lev et al., 2013). Moreover, in
vitro, hyperglycemia has been shown to impair EPC angiogenic feature (Krankel
et al., 2005). Aicher et al, demonstrated NO as an essential factor for the
mobilization of EPCs (Aicher et al., 2003). Since diabetes down-regulate the NO
production, so it may subsequently affect EPC trafficking. Numerous studies
have shown a significant reduction and dysfunction in EPCs associated with
major diabetic micro and macro vascular complication. Fadini et al found that
EPC is dysfunctional in type 2 diabetes and demonstrated a strong correlation
between circulating EPC’s depletion and diabetes peripheral vascular
complication (Fadini et al., 2005; 2006). In diabetic rat model, Yoon et al found

2

that EPC’s defect is one of the other features leading to myocardial VEGF’s
downregulation, which consider as an early event in diabetic cardiomyopathy
(Yoon et al., 2005). Diabetic nephropathy is another diabetic complication related
to EPC dysfunction. Diabetic nephropathy is associated with CD34+ cells
decrease (Makino et al., 2009). Naruse et al have demonstrated an improvement
in nerve vascular support and sciatic nerve conduction in diabetic rats after
intramuscular injection of EPCs derived from human cord blood (Naruse et al.,
2005). Also, neurotropic and angiogenic effect in diabetic mice neuropathy has
established via BM derived EPCs (jeong et al., 2009).
Extracellular microvesicles (MVs) are submicrometric fragments, ranging from
0.1 to 1 µm, released from the cells in response to numerous conditions,
including activation and apoptosis (Mause & Weber., 2010). Circulating
microvesicles (cMVs) are the extracellular MVs released from the cells in the
blood and on the vascular wall. cMVs are found in the blood of healthy donors
and play important roles in intercellular communication. An elevation in cMV
levels has been reported to correlate with several diseases such as, thrombotic
diseases, diabetes, cardiovascular diseases, and renal failure (Burger et al.,
2011; Nomura et al., 2009a & Chen et al., 2011). Furthermore, some studies
showed that the level of cMVs could predict the severity of these diseases
(Rautou et al., 2011). So, cMV levels could serve both as biomarkers and
predictors.
All type of cells release MVs in highly controlled process for specific function.
MVs express certain membrane proteins that reflect their parental cells. It also
3

carries their parent’s cell components, such as membrane, cytoplasm, cytosolic
proteins, and some nuclear component. More important, MVs carry RNAs, such
as mRNA, microRNA, and non-coding (ncRNA) (Mause and Weber., 2010, Diehl
et al., 2012).
The membrane proteins of MVs help to identify their origin by labeling the cell
surface specific antigens. For examples, endothelial progenitor cells-derived
microvesicles (EPC-MVs) can be recognized as CD34+ and vascular endothelial
growth factor receptor-2 (VEGFR-2) + particles. Endothelial microvesicles
(EMVs) can be characterized as CD144+ particles, and MVs from platelet
(PMVs) can be labeled by CD42a or CD42b.
Accumulating evidence support the idea that MVs are able to transfer and deliver
genetic information from their parent cells to the target cells. So, MVs represent a
novel cell-cell communication avenue. MVs could also work as cytokines
container and as mediators of immune response and inflammation (Lee et al.,
2011). The function of MVs is complex and multifactorial, and might depend on
their stimulator and origin. In previous study we establishes that preincubation of
circulating MVs isolated from diabetic mice impairs the function of EPCs from
control mice, whereas, MVs from healthy control does not have that effect on
EPCs (Chen et al, 2011).
Several studies established a direct effect of MVs on ECs. Circulating MVs impair
endothelial relaxation throughout; NO disturbing, inflammation and coagulation
promotion, and apoptosis and angiogenesis alteration (Lovren & Verma., 2013).
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On the opposite, Agouni et al established a restoration to impaired coronary
relaxation in ischemic mouse model after MV administration (Aqouni et al., 2007).
However, few evidence is found about the effect of MVs on EPCs.
Recently, MVs display as a therapeutic target. However, there are conflicted
opinions regarding its positive or negative effect. EPC-MVs are found to be able
to protect the kidney from ischemia-reperfusion injury (Cantaluppi et al., 2012).
Also, EPC- MVs has been reported to have a positive effect on hypoxia/
reoxygenation-induced endothelial dysfunction and apoptosis (Wang et al.,
2012). The EPC-MVs also have been shown to protect cardiomyocyte from Ang
II-induced hypertrophy and apoptosis (Gu et al., 2014). By contrast, EMVs
released under high glucose treatment to ECs have been reported to cause
vascular inflammation in atherosclerotic mouse (Jansen et al., 2013). Similarly,
our laboratory has demonstrated a negative effect of diabetic MVs on EPC
functions. As mentioned, preincubation of circulating MVs isolated from diabetic
mice impairs the function of EPCs (Chen et al, 2011). In this study, we proposed
to investigate both positive and negative effect of MVs depending on their origins
in human study. We have explored whether circulating MVs isolated from the
healthy subjects (ch-MVs), could improve the function of diabetic EPCs (dEPCs). On the other hand, whether diabetic MVs isolated from diabetic patients
(cd-MVs), could impair the function of healthy EPCs (h-EPCs) in vitro.
Furthermore, we have compared the levels of EPCs and EPC-MV in diabetic
patients and healthy subjects.

5

2. HYPOTHESIS AND SPECIFIC AIMS
2.1 Hypothesis
The hypothesis is that Levels of circulating microvesicles modulate endothelial
progenitor cell functions in T2DM by changing their migration ability, apoptosis
rate, and ROS production. Circulating microvesicles from healthy subjects could
improve the function of diabetic EPCs; conversely, circulating microvesicles from
diabetic patients could have the ability to impair the function of EPCs from
healthy subjects.
2.2. Specific aims
Three specific aims associated with this study.
1. Determine the levels of EPC and EPC-MV in diabetic patients and healthy
subjects.
2. Compare the migration ability, apoptosis rate and ROS production in diabetic
and healthy subjects.
3. Determine whether circulating MVs isolated from the blood sample of healthy
subjects (ch-MVs) could improve the function of diabetic EPCs (d-EPCs) and
conversely whether circulating MVs isolated from diabetic patients (cd-MVs)
could impair the function of healthy EPCs (h-EPCs)
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3. MATERIAL AND METHODS
3.1. Study Population
A total of sixteen subjects were included in the study between 25-55 yrs. seven
with type 2 diabetes mellitus (T2DM), and nine were healthy control. Patients
were recruited from the endocrinology department of Dr. Thomas Koroscil at the
Wright State Physicians Internal Medicine building in Dayton, Ohio. The protocol
was approved by the wright state university institutional review board (IRB). Each
patient signed an informed consent after thorough explanation.
Exclusion criteria: pregnancy, patient with history of myocardial infarction, stroke,
unstable angina, renal or heart failure, cancer, chronic alcohol abuse,
hypertension requiring more than 3 antihypertensive medication, use of any
multi-vitamin supplement, and patients with proliferative diabetic retinopathy or
nephropathy or painful diabetic neuropathy requiring chronic narcotic analgesic
therapy. The members of the Department of Pharmacology and Toxicology at
Wright State University Boonshoft school of Medicine, Dayton, Ohio, performed
the study.
3.2 Blood Sampling
After an 8 hour fast, blood samples were drawn. Approximately 60 ml of blood
was obtained through a 20-gauge butterfly needle, which was inserted into a
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forearm vein. Sample was collected in the presence of 3.13% citrate buffer (8ml)
from all subject. The blood samples were directly transferred to the lab and
processed within 1 hour. Samples were also tested for glucose, HbA1c, and lipid
profile.
3.3. Study Design
EPCs and circulating MVs were isolated from each blood sample, then a cross
study was achieved as described in figure 2. Circulating EPCs isolated from
diabetic patients (d-EPCs) cultured for 10-17 days were incubated with fresh
MVs isolated from healthy subjects (ch-MVs). On the other hand, the EPCs
isolated from healthy subjects (h-EPCs) were incubated with diabetic MVs (cdMVs). EPCs were cultured in 24-well plates and co-incubated with 100 µg/ ml of
MVs. After 24-hour incubation, functional assay (migration), apoptosis and ROS
production were performed. The levels of EPCs and circulating MVs were also
measured using the flow cytometry at the day of MV isolation.
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Figure 1. Diagram of the study design. A cross study was achieved. d-EPCs was
incubated with ch-MVs, and h-EPCs was incubated with cd-MVs. Migration
assay, ROS production, and apoptosis were measured in both groups.
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3.4. Circulating EPC Isolation
Peripheral mononuclear cells (MNCs) were used for EPC culture. Briefly, from
peripheral blood, using gradient density centrifugation at 400g for 35 minutes at
4°C, the MNCs in the interface layer were isolated and collected to two new
tubes. The MNCs in the first tube, which was isolated from about 5 ml blood, was
resuspended with 100 µl Phosphate-Buffered Saline (PBS) for the level of EPCs
analysis using flow cytometry. The second was counted and cultured on 24 well
plate at a density of 5 × 106cells/well, and then grown in Endothelial cell Basal
Medium-2 (EBM-2) supplemented with 10% FBS containing EPC growth cytokine
cocktail (Lonza, Walkersville, MD). After 3 days, non-adherent cells were
removed by washing with phosphate buffered saline (PBS). Thereafter, culture
medium was changed every two days, and cells were cultured continuously for
10 to 17 days for MV co-incubation study. The upper layer of gradient density
centrifugation (plasma) was collected for MV isolation.
3.5. Circulating MV Isolation
After gradient density centrifuge for isolation of MNCs, the upper layer, which is
the platelet rich plasma, was collected and centrifuged (1500g, 15 min) at 10°C
to get platelet-free plasma (PFP). PFP was then divided to numerous tubes 1
ml/tube, then centrifuged at 30,000g for 30 min, at 10°C to pellet circulating MVs.
The MV pellet was resuspended in 100 µl PBS for each tube. Some (100 µg/ ml)
were used to co-incubate with EPCs and some were used for flow cytometry
analysis on the same day.
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3.6. Flow cytometry analysis of the level of circulating EPCs and EPC-MVs.
EPCs isolated from 5 ml of blood, and MVs isolated from 1ml of PFP were both
resuspended with 200 µl PBS and divided to two tubes, respectively. One tube of
each group was incubated with anti-human FITC-conjugated CD34 (eBioscience,
San Diego, CA) and anti-human PI-conjugated VEGFR-2 (BD Biosciences, San
Diego, CA). The second tube was incubated with FITC- labelled IgG1
(eBioscience, San Diego, CA) and PI- labelled IgG1 (BD Biosciences, San
Diego, CA), as the isotopic control for color compensation. After incubation in the
dark for 30 min, the percentages of EPCs and EPC-MVs were measured using
flow cytometry (Accuri C6 Flow cytometry, San Jose, USA) as double stained
with CD34 and VEGFR-2.
3.7. Dose- response Study of cd-MVs on h-EPCs Apoptosis Rate
To determine the effective dose of cd-MVs that increase h-EPCs apoptosis rate,
h-EPCs were treated with different doses of cd-MVs (25, 50, 75, 100 µg/ml). After
24h h-EPCs were trypsinized and the apoptosis rate analyzed using flow
cytometer. Bradford assay (Bio-Rad, Hercules, CA) was used to quantify the
protein concentration of cd-MVs.
3.8. Incubation of EPCs with Isolated Circulating MVs
EPCs were prepared, and circulating MVs were isolated as described above.
MVs freshly isolated from 1 ml plasma were resuspended with 100 µl EPC
culture medium. Then EPCs (10-17 day old) were incubated with culture medium
(Vehicle) or 100 µg/ ml of MVs for 24 hours at 37°C before function assays. The
11

dose were determined by dose-response study. The co incubation time
determined by previous animal study.
3.9. Migration Assay
EPC migration function was evaluated using the Boyden chamber system
(Millipore, Temecula, CA). The Boyden Chamber system uses a porous
membrane provides an interface between two chambers. After around 10 days of
EPC culture, EPCs (2 × 104 cells) were detached with trypsin and placed into the
upper compartment of the Boyden chamber, with the porous membrane at the
bottom, and EPC serum free medium in the lower compartment.
Chemoattractants were already placed by the manufacture in the lower chamber,
so the EPCs in the upper chamber should migrate toward the chemoattractant
passing the porous membrane and moving to the other chamber. Circulating
microvesicles solution 100 µg/ ml were added to the upper chamber of
experimental ones. After 24 hour co-incubation, the EPCs that migrated across
the membrane were stained and solubilized with extraction buffer, transferred to
microplate, then read with Optical Density (OD) at a wavelength of 535 nm using
Fusion Packard Reader, where scattered light passes through a cell suspension,
greater scatter indicates more cells present.
3.10. Flow Cytometry Analysis of Cell Apoptosis
The apoptotic rate of h-EPCs and d-EPCs after co-incubation was assessed
using apoptosis assay kit (BD Biosciences, San Diego, CA). After co-incubation,
the cell culture medium was removed and the cells were washed with PBS.
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Cultured EPCs were detached by using 0.5% trypsin for 3-5 min at 37°C. Once
the detachment happened, the complete media was added into the well to stop
the reaction of trypsin and pipetted for several time to obtain single cell
suspension. The cell suspension then centrifuged at 400g for 6 min to pellet the
cells. After discarding the supernatant, pelleted cells were resuspended with 100
µl 1x annexin-binding buffer, and incubated with 5 µl FITC- conjugated Annexin V
and 5 µl Propidium iodide(PI) for 30 min at room temperature in dark. The
labelled cells then analyzed by flow cytometry. The EPCs stained with both
annexin V and PI were considered to be late apoptosis EPCs (the upper right
quadrant), and the cells stained only with annexin V were considered to be early
apoptosis (the lower right quadrant). The apoptosis percentage counted as the
total of both early and late apoptosis percentages. EPCs did not label with any
antibody were used as control.
3.11. Intracellular ROS Production
Intracellular ROS production was determined by Dihydroethidium (DHE; SigmaAldrich, St. Louis, MO) staining. Briefly, cells were incubated with the DHE
working solution (1µM) at 37° for 2 hours in dark. Then the cells were observed
under an inverted microscope, red fluorescence was visualized by a fluorescence
microscopy. After that the cells were washed with PBS twice, detached by using
0.5% trypsin for 3-5 min at 37°C. Once the detachment happened, the complete
media was added into the well to stop the reaction of trypsin and pipetted for
several time to obtain single cell suspension. The cell suspension then
centrifuged at 400g for 6 min to pellet the cells. After discarding the supernatant,
13

pelleted cells were resuspended in 100ul PBS. Then the fluorescence intensity of
cells was analyzed using a flow cytometer.
3.12. Statistical Analysis
All Data was expressed as mean ± SD, and were analyzed using student’s t-test.
Statistica-Academic software Version 12 was used. For all tests, Values of P ˂
0.05 were considered statistically significant.
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4. RESULTS
4.1. Study Participants
A total of sixteen participants were recruited (nine control, seven T2DM) as
shown in table 1. The average of patient’s age was 29± 4 yrs for control and 43±
8 yrs for diabetic patients. There was a significant difference on the age between
two groups (P <0.05). The HbA1c and glucose level was significantly higher in
diabetic patients when compared to healthy control group (glucose: 85.4± 14.4
mg/dl and 155.5± 84.5 mg/dl, control vs. diabetes, P<0.05; HbA1c: 5.4± 0.2 and
7.5± 1.7 % of total HGB, control vs. diabetes, P<0.05). Also the level of
triglycerides and very low density lipoprotein (VLDL) were significantly higher in
diabetic patients (triglycerides: 99.77± 36.7 mg/dl and 157.28± 66.2mg/dl, control
vs. diabetes, P<0.05; VLDL: 19.88± 7.3mg/dl and 31.42± 13.4 mg/dl, control vs.
diabetes, P<0.05). However the level of total cholesterol has no significant
difference between diabetic and control groups (176.88± 33.7 mg/dl and 160.7±
22.7 mg/dl, control vs. diabetes, P>0.05). There were also no significant different
between diabetic and control groups on the level of high density lipoprotein
(HDL) and low density lipoprotein (LDL) (HDL: 50±9.9 mg/dl and 40.7±13.3
mg/dl, control vs. diabetes, P>0.05; LDL: 107± 29.2mg/dl and 88.5± 22.3mg/dl,
control vs. diabetes, P>0.05).

15

Clinical Characteristics of the Studied Population
Characteristics

Healthy Subjects

Patients with
T2DM

Total (n=16)

9

7

Average Age (years)

29±4

43±8*

Sex Ratio (male: female)

(7:2)

(6:1)

Fasting Blood Glucose (MG/DL)

85.4±14.4

155.5±84.5*

HbA1c (% Total HGB)

5.4±0.2

7.5±1*

Total Cholesterol

176.8±36.7

160.7±22.7

Triglycerides.

99.7±36.7

157.2±66.2*

HDL

50±9.9

40.7±13.3

LDL

107±29.1

88.5±22.2

VLDL

19.8±7.3

31.4±13.4*

Lipid Profile (MG/DL)

Table 1. Clinical characteristic of studied population. Abbreviations: HbA1c,
glycated hemoglobin; HDL, High Density Lipoproteins; LDL, Low Density
Lipoproteins; VLDL, Very Low Density Lipoproteins. * Means significant changes
P<0.05.
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4.2. The Level of Circulating EPCs Decreased and EPC-MVs Increased in
Diabetic Patients.
Using flow cytometry analysis, our finding showed that the percentages and the
numbers of circulating EPCs (CD34+and VEGFR-2+) were significantly
decreased in diabetic patient compared to control (3.03 ± 0.41% and 0.76 ± 1%,
or 3119.8 ± 2414.6 and 421.5 ± 364.9 cells/ 1ml of blood. control vs. diabetes,
P<0.01; figure 2A, 2B and 2C.) By contrast, the percentages and the numbers of
circulating EPC-MVs (CD34+and VEGFR-2+) were significantly increased in
diabetic patient when compared to control (1.06 ± 0.58% and 4.3 ± 1.34 % or
2636.8 ± 1914.1 and 8309.2 ± 4122.05 MVs/1ml of plasma. control vs. diabetes,
P<0.01; figure 3A, 3B and 3C).

17

A.

B.

C.

D.
EPC Levels in Diabetic
Patients and Controls

EPC Percentages in Diabetic
4 Patients and Control

6000

EPCs Count

EPCs %
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Control

Diabetic

Diabetic

Mean

Mean

Figure 2. The level of circulating EPCs in diabetic patients and control. The level
of circulating EPCs decreased in diabetic patients compared to control. A, B,
Representative flow cytometry plots showing the level of circulating EPCs in
control (A), and diabetic patient groups (B). C and D Bar charts summarizing the
percentage and level of circulating EPCs respectively, in each group. EPCs were
significantly reduced in diabetic patients compared to controls. *P < 0.05. Data
are expressed as mean ± SD, n=9 for control group, and 7 for diabetic patients.
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A.

B.
C.

C.

D.
EPC-MV Levels in Diabetic
Patients and Controls
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Figure 3. The level of circulating EPC-MVs in diabetic patients and controls. The
level of circulating EPC-MVs elevated in diabetic patients compared to control. A,
B, Representative flow cytometry plot showing the level of circulating EPC-MVs
in control (A), and diabetic patient groups (B). C and D Bar charts summarizing
the percentage and the count of circulating EPC-MVs respectively, in each
group. EPC-MVs were significantly elevated in diabetic patients compared to
controls. *P < 0.05. Data are expressed as mean ± SD. n=9 for control group,
and 7 for diabetic.
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4.3. The Migration Ability of EPCs Decreased in Diabetic Patients.
To determine the difference of the migration ability in control group and diabetic
group, Boyden Chamber Kit was used to detect the migration ability of EPCs in
both groups. Results showed that the migration ability of EPCs from control
group was significantly higher than the ones from diabetic patients. (0.229 ±
0.007 and 0.180 ± 0.025, control vs. diabetes, P<0.05; figure 3).
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Figure 4. The migration ability of EPCs in diabetic patients and control. The
migration ability of EPCs was significantly reduced in diabetic patients compared
to control. *P < 0.01. Data are expressed as mean ± SD, n=3.
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4.4. The Apoptosis Rate of Cultured EPC Increased in Diabetic Patients.
To establish the difference in the apoptosis rate in control group and diabetic
group, flow cytometry analysis was used. Results showed that apoptosis rate of
d-EPCs was significantly higher than that of h-EPCs. (24.15 ± 10.15 and 70.80 ±
8.05 %, control vs. diabetic, P<0.01. Figure 5).
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Figure 5.The apoptosis rate of EPCs in diabetic patients and controls. The
apoptosis rate of EPCs was significantly increased in diabetic patients compared
to control. *P < 0.01. Data are expressed as mean ± SD, n=3.
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4.5. The ROS Production of Cultured EPCs is elevated in Diabetic Patients
To evaluate the ROS production levels of EPCs in diabetic and healthy control,
the DHE staining was used and the levels of ROS were checked under
microscope and measured using a flow cytometer analysis. As shown in Figure 6
A, B, C, and D there were 2 populations, high ROS production population and
low ROS production population. The percentage of ROS production in the
diabetic patients was significantly higher in the high ROS production population
compared to the control (46.05 ± 9.95 and 74.27± 5.32, control vs. diabetic,
P<0.05). No significant change in the low ROS production population.
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Figure 6. The ROS production of EPCs in diabetic patients and control. The ROS
production of EPCs, in the high ROS production population was significantly
increased in diabetic patients compared to control. (A). representative Flow
cytometry plot for control group. B. representative Flow cytometry plot for diabetic
group. C and D. Summarized Data. Data are expressed as mean ± SE±SD, n=4
for diabetic and 2 for control * P <0.05.
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4.6. The Effect of cd-MV Different Doses on the Apoptosis Rate of h-EPCs.
To determine the effective dose of cd-MVs, h-EPCs were treated with different
doses of cd-MVs solution (25, 50, 75,100 µg/ml) for 24h, as seen in figure 7, cdMVs dose dependently increase the cell apoptosis rate. Depend on these data,
we select 100 µg/ ml for the following co- incubation experiments.
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Figure.7.Dose- response study of cd-MVs on h-EPCs apoptosis rate.
Representative scatter plot showing dose dependent effect of cd-MVs on h-EPCs
apoptosis rate.
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4.7. The ch-MVs Enhanced the Migration Ability of d-EPCs
To establish the effect of ch-MVs on d-EPCs mobilization, d-EPCs were
incubated with 36µl/ml of ch-MVs or with vehicle (culture media) in serum free
EBM-2 medium for 24 hours. Boyden Chamber Kit was used to detect the
migration ability of EPCs. Results showed that incubation with ch-MVs
significantly improved the migration ability of d-EPCs, (0.18± 0.02 and 0.24± 0.3,
vehicle vs. ch-MVs, P<0.05; figure 7).
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Figure.8.The effect of ch-MVs on d-EPCs migration ability. Preincubation of dEPCs with ch-MVs (36ul/ml; 24 h) were significantly increased the migration
ability of EPCs. Summarized data for the migration. n=3. * P <0.05. Data are
expressed as mean ± SD.
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4.8. The ch-MVs Decreased the Apoptosis Rate of d-EPCs
According to flow cytometry analysis, 24 hours incubation of d-EPCs with 36µl/ml
ch-MV significantly decreased the rate of apoptosis in d-EPCs when compared to
vehicle, Figure 8A, 8B, and 8C. (72.1± 3.4 and 57.3± 9.7%. vehicle vs. ch-MVs,
P<0.05).
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Figure 9.The effect of ch-MVs on d-EPCs apoptosis rate. Preincubation of dEPCs with ch-MVs (36ul/ml; 24 h) were significantly decreased the apoptosis
rate of d-EPCs compare to vehicle. (A). Representative flow cytometry plot
showing the d-EPCs in vehicle group. (B). Representative flow cytometry plot
showing the d-EPCs in MV co-incubation group. (C). Bar chart summarizing the
apoptosis rate in d-EPCs in vehicle and MV treatment group, n=4. * P <0.05.
Data are expressed as mean ± SD.
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4.9. The Effects of ch-MVs on the ROS production of d-EPCs
To evaluate the effect of ch-MVs on the levels of ROS production in d-EPCs, the
d-EPCs were co-incubated with ch-MVs (100µg/ml) for 24 hrs. The levels of ROS
were checked under microscope and analyzed using flow cytometry method. As
shown in Figure 9A there were 2 populations, high ROS production population
and low ROS production population. The percentage of ROS production in the
co-incubation group was significantly decreased in the high ROS production
population compared to the vehicle group (74.3± 10.6 and 61.5± 14.5, vehicle vs.
ch-MVs, P<0.05). In the contrast, the percentage of ROS production was
significantly increased in the low ROS production population when compared to
the vehicle group (25.8± 10.4 and 37.2± 12.8, vehicle vs. ch-MVs, P<0.05).
These data suggest that ch-MV could decrease the ROS production of db-EPCs
by decrease the high ROS production population and increase the low ROS
production population. (Figure 9B, P ˂ 0.05 n=4). Figure 9C showing the
significant change in high population, and 9D showing the significant change in
low population.
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Figure 10. The effect of ch-MVs on d-EPCs ROS production. Preincubation of dEPCs with ch-MVs (100ug/ml; 24 h) were significantly decreased the ROS
production in the high ROS production population of d-EPCs, and increase it in
the low ROS production population, compare to vehicle. (A). Representative flow
cytometry plot for vehicle group. B. Representative flow cytometry plot for coincubation group. C and D. Summarized Data, n=4. * P <0.05. Data are
expressed as mean ± SE±SD.
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4.10. The effect of cd-MVs on the Migration Ability of h-EPCs.
As before, to establish the effect of cd-MVs on h-EPCs mobilization, h-EPCs
were incubated with 36µl/ml of cd-MVs or with vehicle in serum free EBM-2
medium, for 24 hours using Boyden Chamber Kit. Results are shown in figure 10,
after incubation with cd-MVs, the migration ability of h-EPCs has no significant
change when compared to vehicle group. (0.22 ± 0.007and 0.19± 0.017%,
vehicle vs. cd-MVs, P>0.05).
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Figure.11.The effect of cd-MVs on h-EPCs migration. Preincubation of h-EPCs
with cd-MVs (100ug/ml; 24 h) not significantly decrease the migration ability of hEPCs. Summarized data for the migration. n=3. P > 0.05. Data are expressed as
mean ± SD. (fold of changes).
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4.11. The cd-MVs Increased the Apoptosis Rate of h-EPCs.
According to flow cytometry analysis, 24 hours incubation of h-EPCs with
100µl/ml cd-MV significantly increased the apoptotic rate when compared to
vehicle. (24.05 ± 9.9 and 42.7± 3.4 vehicle vs. with cd- MVs, P<0.05; Figure 11
A, B and C).
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Figure 12. The effect of cd-MVs on h-EPCs apoptosis rate. Preincubation of hEPCs with cd-MVs (36ul/ml; 24 h) significantly increases the apoptosis rate of hEPCs compare to vehicle. (A). Representative flow cytometry plot showing the hEPCs in vehicle group. (B). Representative flow cytometry plot showing h-EPCs
treated with cd-MVs. (C). Bar chart summarizing the apoptotic rate in h-EPCs in
vehicle group vs. in cd-MVs group, n=4. * P <0.05. Data are expressed as mean
± SD.
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4.12. The Effects of cd-MVs on the ROS production of h-EPCs
As previous, to evaluate the effect of cd-MVs on the levels of ROS production of
h-EPCs, the h-EPCs were co-incubated with cd-MVs (100µg/ml) for 24 hrs The
levels of ROS were determined by DHE staining and were checked under
microscope and analyzed using flow cytometry method. As shown in Figure 12,
again there were 2 populations, high ROS production population and low ROS
production population. The percentage of ROS production in the co-incubation
group was significantly increased in the high ROS production population
compared to the vehicle group (43.65± 18 and 68.4± 15, vehicle vs. cd- MVs,
P<0.05). In the contrast, the percentage of ROS production was not significantly
decreased in the low ROS production population when compared to vehicle
group (51.2± 23.4 and 30.6± 14.4, vehicle vs. with cd-MVs, P >0.05; Figure 12,
n=2)
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Figure 13. The effect of cd-MVs on h-EPCs ROS production. Preincubation of hEPCs with cd-MVs (100ug/ml; 24 h) significantly increases the ROS production in
the high ROS production population of h-EPCs. There was non-significant
decrease in the low ROS production population, compare to vehicle. (A).
Representative flow cytometry plot for vehicle group. B. Representative flow
cytometry plot for co-incubation group. C and D. Summarized Data, n=2. * P
<0.05 for c only. Data are expressed as mean ± SE±SD.
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5. DISCUSSION.
There are four new findings for this study. First, the level of CD34+VEGFR+ MVs,
which known as EPC-MVs, is elevated in diabetic patient compared to healthy
subject and the level of EPCs is decreased. Second; the migration ability of dEPCs were decreased, and the apoptosis rate and ROS production were
increased in d-EPCs. Third; ch-MVs derived from healthy subject can improve
the migration function of EPCs from diabetic patients and are able to decrease
their apoptotic rate. In contract, cd-MVs derived from diabetic patients increase
EPC apoptosis without affect the migration ability. Fourth; MV treatment can
modulate ROS production of EPCs.
Diabetic environment including hyperglycemia, hyperlipidemia, and insulin
resistance in type 2 diabetes mellitus patient, trigger and increase the oxidative
stress, which targeting ECs and causing endothelial dysfunction leads to various
cardiovascular complications (Tousoulis et al., 2012). Endothelium dysfunction is
a key initiator for vascular injury, which is characterized by a pro-inflammatory,
pro-coagulative, and pro-vasoconstrictive endothelial constitution. (Burger et al.,
2012). EPCs play an important role in maintaining endothelium hemostasis,
integrity and regenerate injured cells.
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There are many studies have reported that the number and function of EPCs in
diabetic patients and mice are decreased and impaired (Krankel et al., 2005;
Fadini et al; 2006, Makino et al., 2009 & Tramontano et al., 2010). However until
now the study determining the exact mechanism is lacking. Therefore, knowing
EPC number and better understand of their function, as well as the mechanism
by which diabetes deplete EPCs and impair their function, are very important for
preventing and controlling cardiovascular complications in diabetes. Our previous
study on mice find the decrease in circulating EPCs (Chen et al., 2011). To
deepen previous finding, in the present study we evaluate the levels of circulating
EPCs in diabetic patients. Our data showed that the level of circulating EPCs is
reduced in diabetic patients compare to the healthy subjects. Moreover, we found
that the migration ability of d-EPCs were decreased too, compare to an increase
in the apoptosis rate and ROS production.
Improvement of EPC level and function could be very helpful for preventing and
treating diabetic-related cardiovascular diseases. Previous studies are focusing
on genetic transfection and chemokine stimulation to improve EPC function
(Song et al., 2009; Kuliszewski et al., 2011 & Mohle et al., 1998). Our study
group, in previous study, has demonstrated that over-expression of CXCR4 on
EPCs could improve the EPC function which are impaired in db/db mice (Chen et
al., 2012). Besides enhancing the EPC function, EPC transplantation is an
effective therapeutic tool for the endothelial dysfunction, which is an imitation
factor of cardiovascular diseases. The therapeutic effects of EPC transplantation
include two beneficial facets. One is the physical replacement of injured ECs and
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promotes the angiogenesis. The second is the secretion of supporting cytokines
to promote repair and angiogenesis. More recently, some research reported that
the mechanism might be partially ascribed to EPC released vesicles.
MVs are submicrometric fragments derived from different types of cells and
tissues. Cell types shed MVs in response to activation, apoptosis and stress.
MVs express certain membrane proteins, which reflect their cell origin and
stimulator. Accumulating evidence demonstrated that the level of MVs could be
used as biomarkers for disease process and outcome. Our previous study find
that the decrease in EPCs and the increase in EPC-MVs (Chen et al., 2011).
In this human study, likewise we goes beyond the circulating level of EPCs, and
measured the level of EPC-MVs. Circulating EPC-MVs could be the indicator of
impairment or incompetence EPC (Pirro et al., 2008). Considering
CD34+VEGFR+ MVs as EPC-MV, and using flow cytometry, which is a wellknown method, to evaluate MV level, we revealed that the level of EPC-MVs is
increased in diabetic patients compared to healthy subjects. These finding raises
the concept of using MV levels as a biomarker to some diseases. A possible
interpretation of EPC levels decrease and EPC-MV levels increase is a higher
rate of EPCs breakdown into EPC- MV in diabetes.
Most important, MVs present a novel cell- cell communication avenue. They
carry and transfer the parent information to the received cell, which could
modulate the target cell function. Moreover it can be used as a therapeutic
approach. However, MVs have both beneficial and detrimental biologic effects.
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Some studies have shown positive effects for MVs, while others showed negative
effects, which is depends on the origins and the stimulus (Lovren & Verma,
2013). For example, EMVs generated by using starvation as ECs stimulator,
protect ECs from apoptosis induced by camptothecin, by way of p38 MAPK
activation inhibition (Jansen et al., 2012). By contrast, EMVs released by ECs
treatment with high glucose have deleterious effects recognized as, adhesion
proteins expression increase and enhanced macrophage infiltration in an
atherosclerotic mouse model (Jansen et al., 2013). Constantly, our previous
study showed that circulating MVs derived from diabetic mice could impair EPC
functions such as migration and tube formation in vitro and in vivo, whereas, the
MVs from healthy control mice do not have those detrimental effects (Chen et al.,
2011). Similarly, platelet microvesicles (PMVs) isolated from healthy subjects
promotes post-ischemic angiogenesis and revascularization in a myocardial
ischemic rat (Brill et al., 2005), while PMVs, isolated from blood stored for
transfusion, may cause thrombosis in recipients during the transfer process
(Simak & Gelderman., 2006). EPC-MVs released under serum deprivation stress
had protective effects on hypoxia/reoxygenation-induced brain microvascular EC
dysfunction and apoptosis; whereas, EPC-MVs produced under apoptotic
stimulation induced by tumor necrosis factor-𝛼 had opposite effects (Wang et al.,
2013).
It is known that the level of many circulating MVs is elevated in diabetes such as
endothelial MVs, platelet MVs, and monocytes MVs (Nomura et al., 2009b).
However, it is still not completely understood whether diabetic MVs have a
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positive or negative effects on EPC Function. Establishing a positive effect of
MVs on EPCs might be the miracle to endothelial dysfunction restoration. Also,
knowing that diabetic MVs have a depraved effect on healthy EPCs could
promote a big concern in the prevention prospective. Moreover, the research
conducted on human samples is still blank. For address our hypothesis that MVs
can improve or impair EPC function depending on its origin, we create a cross
study where d- EPCs incubated with ch- MVs, and h- EPCs incubated with cdMVs. The function (migration), ROS production and apoptosis of EPCs of two
groups were evaluated after co-incubation. Our present study for the first time
demonstrated that human circulating MVs derived from healthy subject have
positive effect on human diabetic EPCs; while, the human diabetic MVs have
negative effect on human EPCs isolated from healthy subjects. This agrees with
and provides with further information of our previous study demonstrates an
impairment of EPC function by co-incubating with circulating MVs from diabetic
mice (Chen et al., 2011).
As known EPCs migrate from BM toward ischemic tissue or injured ECs, to be
involved in EC regeneration (Urbich and Dimmeler., 2004). EPC migration
impairment and endothelial dysfunction, both have established in diabetic
patients (Menegazzo et al., 2012). Our data showed that 24 hours preincubation
of diabetic EPCs with ch-MVs improves the migration ability of diabetic EPCs.
Since improving the migration process would enhance EPC ability to restore
endothelium, and avoid vascular complication in diabetes, this is a very important
finding for further research to use it as endothelial dysfunction’s restoration
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avenue. These results suggest that the circulating MVs derived from different
origins might carry different contents which exert oppose effects on EPCs. Our
future research will focus on finding the different contents, such as proteins,
mRNAs and miRNAs in these two types of MVs by using Mass spectroscopy,
RNA sequencing.
For the mechanisms responsible for these effects, we observed the ROS
production and apoptosis of EPCs after different MV treatment. It has becomes
widely accepted that enhanced oxidative stress is responsible for EPC number
and function reduction in diabetes and cardiovascular diseases (Lin et al., 2013;
Rossig et al., 2004 & He et al., 2004). Also accumulating evidence showed MV
elevation in diabetic and cardiovascular diseases (Lovern and Verma., 2013).
MVs could be the missing link in this process; they might be involved regulating
of ROS production. Agouni et al have found that activated T- cells derived MVs
showing an ability to decrease ROS and increase NO production (Agouni et al.,
2007). Conversely, Brodsky et al have found that MVs decrease NO production,
and increase superoxide anion O2- (Brodsky et al., 2004). Also monocyte-MVs
mediate ROS production in ECs through eNOS uncoupling, NADPH oxidase,
xanthine oxidase, and cyclo-oxygenase (Essayagh et al., 2007). Burger et al
concluded that MVs have the ability to modulate ROS production, through
different mechanisms. The stimulator and the origin for MV release both plays a
crucial role in this process (Burger et al., 2012). These provide the rational for our
findings. Our data showing an ability of MV to alter ROS production depends on
its origin and stimulator. Different MVs incubation changed the ratio of ROS
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production. ch-MVs down-regulate ROS production. In contrast, cd-MVs
increased the ratio of ROS production. Taken together, we might conclude that in
normal situation MVs have positive effects on diabetic EPCs. They protect EPC
against oxidative stress and enhance its function by decreasing ROS production.
As we know, EPCs impairment and oxidative stress lead to endothelial
dysfunction and the destructive sequence. Having that in mind, MVs could be
considered the revolutionary treatment for ROS-mediated EPC dysfunction in
diabetes and diabetic cardiovascular complications.
In addition, apoptosis known as the downstream mechanism of MV-mediated
function. MVs isolated from hypertensive patients induce EC apoptosis (Huang et
al, 2010). Also Jorg et al establish that MVs derived from activated ECs induce
apoptosis in circulating angiogenic cells (Distler et al,. 2011). Caspase 3 has
been reported to be the related mechanism. For examples, MVs are able to
deliver Caspase 3 to the target cells and induce apoptosis (Digant-George &
Boulanger., 2011, Hussein et al., 2005; 2007). In contrast, Gatti et al established
a protective effect against apoptosis of mesenchymal cell derived MVs (Gatti et
al., 2011). In our study, apoptosis level was another mechanism to evaluate the
MV function after co-incubation. As we expected, the ch-MVs have the ability to
attenuate apoptosis in d-EPCs. By contrast, cd-MVs increase the apoptosis
levels. These finding in agreement with our previous study that circulating MVs
from diabetic mice impairs the function of EPCs. We believe that ROS production
might be one of the responsible mechanisms for apoptosis level changes. From
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these, we may conclude that the origin of MVs and the environment involved in
their release consider the most critical factors that determine the function of MVs.
This study is the first study to evaluate the effect of human cMVs on human
EPCs, however it has several limitations. First, we used circulating MVs, so we
cannot identify which type of MVs is responsible for the effects. Second, we did
not test the effect of circulating diabetic-MVs on d-EPCs, in comparison the effect
of circulating healthy-MVs on h-EPCs. For the future study, we will expand the
number of participants and explore the contents of cMVs and their mechanism of
that action.
6. CONCLUSION
Taken all together, we conclude that the level of EPCs is decreased, and the
level of EPC-MVs is elevated in diabetic patients. The MVs from healthy subject
could improve the function of diabetic EPCs, in contrast, MVs from diabetic
patients may impair the EPC function from healthy control. The mechanism for
these effects might via the ROS production and apoptosis.
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